A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa

NCT04019041 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa
Acne Inversa
Suppurative Hidradenitis

Interventions

DRUG: bermekimab
DRUG: placebo

Sponsor

Janssen Research & Development, LLC